Stefan Laufer

First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer

Design, Synthesis, and Unprecedented Interactions of Covalent Dipeptide-Based Inhibitors of SARS-CoV-2 Main Protease and Its Variants Displaying Potent Antiviral Activity

A “Ligand First” Approach toward Selective, Covalent JNK2/3 Inhibitors

Uncovering α-Selectivity for Liver X Receptor Agonists for Lipotoxic Cancer Therapies

Azapeptide-Based SARS-CoV-2 Main Protease Inhibitors: Design, Synthesis, Enzyme Inhibition, Structural Determination, and Antiviral Activity

Discovery of the First Highly Selective 1,4-dihydropyrido[3,4-<i>b</i>]pyrazin-3(2H)-one MKK4 Inhibitor

A twist in the tale: shifting from covalent targeting of a tyrosine in JAK3 to a lysine in MK2

4-[5-(4-Fluorophenyl)-1,2-oxazol-4-yl]pyridine

First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure

Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors

The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma

Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in <i>KRAS</i> -mutant cancers

Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on S _N Ar Electrophiles

Probing the Protein Kinases′ Cysteinome by Covalent Fragments

Design, Synthesis, and Biochemical Evaluation of Novel MLK3 Inhibitors: A Target Hopping Example

Untersuchung der Adressierbarkeit des Cysteinoms der Proteinkinasen durch Kovalente Fragmente

A Defined Diet Combined with Sonicated Inoculum Provides a High Incidence, Moderate Severity Form of Experimental Autoimmune Encephalomyelitis (EAE)

Design and Optimization of Novel Benzimidazole- and Imidazo[4,5-<i>b</i>]pyridine-Based ATM Kinase Inhibitors with Subnanomolar Activities

Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure–Activity Relationships, Antiviral Activity, and X-ray Structure Determination

ACKR3 regulates platelet activation and ischemia-reperfusion tissue injury

Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor

Development of novel urea-based ATM kinase inhibitors with subnanomolar cellular potency and high kinome selectivity

Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitors

Pharmacokinetic Optimization of Small Molecule Janus Kinase 3 Inhibitors to Target Immune Cells

LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer

Controlling the Covalent Reactivity of a Kinase Inhibitor with Light

Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration

Design, Synthesis and Biological Evaluation of Novel Pyrazolo[1,2,4]triazolopyrimidine Derivatives as Potential Anticancer Agents

Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3β Inhibitors

Design and Synthesis of Highly Selective Brain Penetrant p38α Mitogen-Activated Protein Kinase Inhibitors